報價延遲最少15分鐘:2026/09/01 03:01 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
799.08 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
40.41/54.16
|
|
企業價值
84.47B
|
| 資產負債 |
|
每股賬面淨值
308.01
|
| 現金流量 |
|
現金流量率
0.06
|
| 損益表 |
|
收益
14.34B
|
|
每股收益
127.21
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners. |
